[Research Progress on the Regulatory Mechanism of Respiratory Microbiota in the  Comorbidity of Chronic Obstructive Pulmonary Disease and Lung Cancer].

Yin Zhang, Tianming Zhang, Hong Wang

Abstract readReviewEnglish Abstract

In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yin ZhangThe Second Clinical Medical School of Lanzhou University, Lanzhou 730030, China.

Tianming ZhangDepartment of Respiratory and Critical Care Medical, The Second Hospital of Lanzhou University, Lanzhou 730030, China.

Hong WangDepartment of Respiratory and Critical Care Medical, The Second Hospital of Lanzhou University, Lanzhou 730030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both chronic obstructive pulmonary disease (COPD) and lung carcinoma (LC) are major public health challenges in China. With the continuous advancement of microbial detection methods, the role of the respiratory microbiome in the pathogenesis and progression of respiratory diseases has become increasingly prominent. This article systematically reviews the dynamic characteristics of the respiratory microbiome during the progression of COPD and LC, then explores its crucial bridging role in COPD-LC comorbidity through mechanisms such as persistently driving chronic inflammation, mediating genomic damage, and participating in immune regulation. The aim is to deepen the understanding of the respiratory microbiome, and to provide new perspectives for optimizing existing treatment strategies, exploring microbial biomarkers for early cancer screening, and improving the clinical management of chronic respiratory diseases. .

Indexed as

Lung NeoplasmsMicrobiotaPulmonary Disease, Chronic ObstructiveRespiratory SystemAnimalsComorbidityHumansChronic obstructive pulmonary diseaseLung neoplasmsRegulatory mechanismRespiratory microbiota

Identifiers

PMID41777065

DOI10.3779/j.issn.1009-3419.2025.106.33

PMCPMC12972577

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.